Technological competitiveness of regenerative medicine was evaluated. We
used mainly the US patent data for the analysis. US patent data can be very
useful for evaluating national competitiveness in most of technological areas.
As a result, Korea was the tenth country in the world equal to Belgium, higher
than the twelfth in C12N area. Usually C12N area can be recognized as
representing biotechnology. When comparing to C12N area, most of countries
except the United States showed the lower technological competitiveness.
Especially, the Japanese technological competitiveness in the regenerative
medicine became much lower than those of other countries. However, some
countries like Canada, Great Britain and France seemed to have the higher
technological competitiveness in regenerative medicine.
We also analysed changes in role of institutions. The patents applied by
hospitals was two times more than those applied by governmental research
institutes. This trend in regenerative medicine was different from that of C12N
area. This fact implies that the role of hospitals in regenerative medicine R&D
can be more important comparing to biotechnology.
In order to analyze which areas can have the more promising business
opportunities, we compared the patent ratio by value chains in each three
sub-areas including stem cell, xenotransplantation and artificial organs. As the
below figure shows, each sub-area has a different patent ratio by value chains.
Stem cell has a peak in the basic science, xenotransplantation in development and
artificial organs in applications such as production of relevant cells and organs.
The above results was confirmed through a case study about heart diseases.
However, most of the countries except Germany and France showed the lower
technological competitiveness in regenerative medicine comparing to that of the
United States. This implies that most of countries could have a technology gap
between discoveries of basic knowledge and application to practises.
Some policy implications were proposed. First, the R&D investment on
regenerative medicine have to be increased. Second, R&D portfolio in Korea need
to be restructured in order to be coherent with technological trends in other
countries. Third, the competitiveness in medical services in Korea must be
developed in order to foster commercialization of regenerative medicine
technologies. Fourth, an increased R&D investment on artificial organs is needed.
We reviewed the definition and the recent development of translational
research in the United States and proposed some policy implications, and also
introduced a case study about the socio-economic impacts of some regenerative
medicine technologies carried out by US Department of Commerce.
- 우리나라의 재생의학 기술경쟁력 평가(An evaluation of technological competitiveness in regenerative medicine)
- Ahn, Doo-Hyun; Chung. Kio-Min; Shin, Yule안두현; 정교민; 신율
우리나라의 재생의학 기술경쟁력 평가(An evaluation of technological competitiveness in regenerative medicine)
서울 : 과학기술정책연구원
|Series Title; No||정책연구 / 06-14|
|Subject Country||South Korea(Asia and Pacific)|
|Subject||Social Development < Health|